Patient enrolment into a study of a drug designed to treat adults aged 60 or over who have been diagnosed with acute myelogenous leukaemia (AML) has been completed, it has been announced.

Genzyme Corp said it had recruited 109 patients who have not previously received treatment for the condition into its phase II clinical trial of Clolar, which is being conducted at research centres across the US.

All participants have at least one "adverse prognostic" factors, such as a prior hematological disorder or poor health and will received an intravenous dose of the drug every day for five days, before being assessed for their suitability to undergo further treatment.

In a statement, the firm said the trial is "designed to address a high unmet medical need among older AML patients who currently have limited treatment options".

Developing in the bone marrow, the US National Library of Medicine and the National Institutes of Health reports AML is one of the most common types of adult leukaemia.

Healthcare providers who have patients who require immediate access to medicines can contact Masters, who has more than 20 years experience in helping medical professionals obtain drugs still undergoing clinical trials.